AC Immune SA (NASDAQ:ACIU) is at least 45.23% than its current record low price of $3.25. There was a -4.65% decline on 4/17/2019 that led the price to move at $4.72. At a recent session, the prices were hovering between $4.52 and $4.97. This company shares are 110.59% off its target price of $9.94 and the current market capitalization stands at $311.8M. The recent change has given its price a 3.56% lead over SMA 50 and -72.87% deficit over its 52-week high. The stock witnessed 3.96% gains, -58.92% declines and -46.79% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ACIU’s volatility during a week at 7.29% and during a month it has been found around 5.56%.

AC Immune SA (ACIU) Top Holders

Institutional investors currently hold around $101 million or 38.2% in ACIU stock. Look at its top three institutional owners: Fmr Llc owns $27.78 million in AC Immune SA, which represents roughly 8.91% of the company’s market cap and approximately 27.51% of the institutional ownership. Similar statistics are true for the second largest owner, Temasek Holdings (Private) Ltd, which owns 2,614,095 shares of the stock are valued at $12.94 million. The third largest holder is Duquesne Family Office Llc, which currently holds $12.33 million worth of this stock and that ownership represents nearly 3.96% of its market capitalization.

AC Immune SA 13F Filings

At the end of December reporting period, 22 institutional holders increased their position in AC Immune SA (NASDAQ:ACIU) by some 2,621,336 shares, 19 decreased positions by 1,455,471 and 7 held positions by 16,239,453. That puts total institutional holdings at 20,316,260 shares, according to SEC filings. The stock grabbed 15 new institutional investments totaling 1,093,187 shares while 9 institutional investors sold out their entire positions totaling 704,114 shares.

AC Immune SA (ACIU) Analyst Guide

Several analysts have released their opinion on AC Immune SA (NASDAQ:ACIU), with 2 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.75 average brokerage recommendation [T1].